Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
(/* Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents {{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberg) |
(/* Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents {{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberg) |
||
Line 17: | Line 17: | ||
{{cquote| | {{cquote| | ||
* Consider drug therapy in children >10 years of age (usually wait until menarche for females) and after a 6- to 12-month trial of fat- and cholesterol-restricted dietary management. | * Consider drug therapy in '''children >10 years of age''' (usually wait until [[menarche]] for females) and after a '''6- to 12-month trial of fat- and cholesterol-restricted dietary management'''. | ||
* Consider drug therapy if | * Consider drug therapy if | ||
**LDL level remains >4.90 mmol/L (190 mg/dL) or | ** [[LDL]] level remains ''>4.90 mmol/L (190 mg/dL)''' or | ||
**LDL remains >4.10 mmol/L (160 mg/dL) and there is a positive family history of premature cardiovascular disease >2 other risk factors are present in the child or adolescent after vigorous attempts to control these risk factors. | ** [[LDL]] remains '''>4.10 mmol/L (160 mg/dL)''' and there is a positive family history of '''premature cardiovascular disease''' >2 other risk factors are present in the child or adolescent after vigorous attempts to control these risk factors. | ||
* Referral to specialized lipid center may be deemed appropriate. | |||
* | * '''Treatment goal''' | ||
** Minimal, LDL '''<3.35 mmol/L (130 mg/dL)''' | |||
** Ideal, LDL '''<2.85 mmol/L (110 mg/dL''' | |||
}} | }} | ||
Revision as of 13:53, 29 October 2011
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Template:DiseaseDisorder infobox
WikiDoc Resources for Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DONOT EDIT)
“ |
|
” |
References
- ↑ McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.